HBK Investments’s Charles River Laboratories CRL Stock Holding History

HBK Investments’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-13,700	Closed	-$1.55M	–	1109
2018 Q4	$1.55M	Buy	+13,700	New	+$1.72M	0.02%	548
2017 Q4	–	Sell	-3,892	Closed	-$420K	–	996
2017 Q3	$420K	Buy	3,892 +1,872	+93%	+$192K	﹤0.01%	826
2017 Q2	$204K	Sell	2,020 -5,992	-75%	-$552K	﹤0.01%	882
2017 Q1	$721K	Sell	8,012 -28,125	-78%	-$2.39M	0.01%	463
2016 Q4	$2.75M	Buy	36,137 +33,437	+1,238%	+$2.54M	0.03%	288
2016 Q3	$225K	Buy	+2,700	New	+$226K	﹤0.01%	778
2016 Q2	–	Sell	-17,777	Closed	-$1.35M	–	977
2016 Q1	$1.35M	Buy	+17,777	New	+$1.32M	0.01%	524
2014 Q3	–	Sell	-15,000	Closed	-$803K	–	970
2014 Q2	$803K	Buy	+15,000	New	+$823K	0.02%	571

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

HBK Investments's CRL Position: Q1 2019 in Review

HBK Investments sold out of Charles River Laboratories (CRL) in Q1 2019, closing a stake of 13,700 shares — an estimated $1.55M sold.

HBK Investments first reported a position in CRL in Q2 2014 and held it in 8 quarters. The position peaked at $2.75M in Q4 2016. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

HBK Investments reported no remaining Charles River Laboratories position as of Q1 2019 after selling out during the quarter.
HBK Investments sold 13,700 Charles River Laboratories shares in Q1 2019, an estimated $1.55M.
HBK Investments first reported a position in Charles River Laboratories in Q2 2014 and held it in 8 quarters.
HBK Investments's Charles River Laboratories position peaked at $2.75M in Q4 2016.
409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on HBK Investments's 13F filing for Q1 2019, filed 15 May 2019.